Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.

ABSTRACT:

Background

Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in placebo-controlled trials of patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).

Objective

To evaluate whether SGLT2 inhibitors and GLP-1 RAs are associated with differential cardiovascular benefit among T2D patients with and without CVD.

Design

Population-based cohort study.

Setting

Medicare and 2 U.S. commercial claims data sets (April 2013 to December 2017).

Participants

1:1 propensity score-matched adult T2D patients with and without CVD (52 901 and 133 139 matched pairs) initiating SGLT2 inhibitor versus GLP-1 RA therapy.

Measurements

Primary outcomes we

SUBMITTER: Patorno E 

PROVIDER: S-EPMC8969214 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature